Other OTC - Delayed Quote USD

Kiromic BioPharma, Inc. (KRBP)

3.1100 +0.0300 (+0.97%)
At close: May 17 at 12:41 PM EDT
Loading Chart for KRBP
DELL
  • Previous Close 3.0800
  • Open 3.0765
  • Bid --
  • Ask --
  • Day's Range 3.0200 - 3.1100
  • 52 Week Range 0.1600 - 5.4900
  • Volume 11,719
  • Avg. Volume 4,090
  • Market Cap (intraday) 4.006M
  • Beta (5Y Monthly) 1.98
  • PE Ratio (TTM) --
  • EPS (TTM) -12.5900
  • Earnings Date Aug 12, 2024 - Aug 16, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Kiromic BioPharma, Inc., a clinical stage biotherapeutics company, utilizes engineered and non-engineered Gamma Delta T cell (GDT) technologies to develop therapies for solid tumors. The company develops Deltacel-01, which is in Phase 1 clinical trial, for patients with non-small cell lung cancer; Isocel in combination with low-dose radiation to treat Mesothelin Isoform 2 positive solid malignancies; ALEXIS-ISO-1, an allogeneic GDT therapy product that targets an isoform of mesothelin; Procel in combination with low-dose radiation to treat PD-L1 positive solid malignancies; and ALEXIS-PRO-1, an allogeneic GDT therapy product that targets PD-L1. It has a license agreement with Longwood University; and a research and development collaboration agreement with Molipharma, S.R.L. The company was formerly known as Kiromic, Inc. and changed its name to Kiromic BioPharma, Inc. in December 2019. Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas.

kiromic.com

35

Full Time Employees

December 31

Fiscal Year Ends

Recent News: KRBP

Performance Overview: KRBP

Trailing total returns as of 5/17/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

KRBP
257.47%
S&P 500
11.18%

1-Year Return

KRBP
19.22%
S&P 500
29.04%

3-Year Return

KRBP
98.21%
S&P 500
27.06%

5-Year Return

KRBP
99.12%
S&P 500
52.23%

Compare To: KRBP

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: KRBP

Valuation Measures

Annual
As of 5/17/2024
  • Market Cap

    4.01M

  • Enterprise Value

    13.91M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -103.26%

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -23.5M

  • Diluted EPS (ttm)

    -12.5900

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    3.2M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -14.23M

Research Analysis: KRBP

Company Insights: KRBP

Research Reports: KRBP

People Also Watch